Search Results
Your search for all items matches 34730 pages
Showing 22901 - 22950Is Second-Line Ramucirumab of Benefit in Advanced Hepatocellular Carcinoma?
In an exploratory analysis of the REACH trial in advanced hepatocellular carcinoma reported in JAMA Oncology, Zhu et al found a borderline survival benefit of second-line ramucirumab (Cyramza) vs placebo among patients with a Child-Pugh score of 5 and a significant benefit among patients with a...
Good CNS Response to Alectinib Reported in Previously Treated ALK-Positive Non–Small Cell Lung Cancer
In a pooled analysis reported in the Journal of Clinical Oncology, Gadgeel et al found that alectinib (Alecensa) was associated with good central nervous system (CNS) response in patients with ALK-positive non–small cell lung cancer (NSCLC) previously treated with crizotinib (Xalkori). Study ...
African American Cancer Survivors More Likely to Experience Lasting Debt Related to Cancer and Its Treatment
African American cancer survivors are more likely than whites to experience lasting debt or forgo necessary medical care as they struggle with the financial burden of cancer, while whites are somewhat more likely to use existing assets to pay for their cancer care, according to a study (C13)...
Affordable Care Act Increased Access to Cancer Care and Clinical Trial Participation Among Hispanics
Implementation of the Affordable Care Act (ACA) in California may have led to a significant increase in the number of Hispanic breast cancer patients at a National Cancer Institute (NCI)-designated cancer center and an increase in the number of Hispanic women who consented to participate in a...
Improved Failure-Free Survival Reported With Addition of Induction Chemotherapy to Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet Oncology, Sun et al found that adding induction treatment with cisplatin, fluorouracil (5-FU), and docetaxel (TPF) to concurrent chemoradiotherapy improved failure-free survival in locoregionally advanced nasopharyngeal carcinoma. Study Details...
Modified Staging System for Pancreatic Neuroendocrine Tumors
As reported in the Journal of Clinical Oncology, Luo et al found that a modified staging classification based on the European Neuroendocrine Tumor Society (ENETS) and the American Joint Committee on Cancer (AJCC) staging classifications may improve distinction among risk groups in pancreatic...
Meta-analysis Shows Association of Minimal Residual Disease–Negative Status With Improved Survival in Multiple Myeloma
In a meta-analysis reported in JAMA Oncology, Munshi et al found that minimal residual disease (MRD)-negative status was associated with improved survival in patients with newly diagnosed multiple myeloma. For the analysis, a literature search identified 21 English language articles published...
Extended Active Surveillance Prior to Systemic Therapy May Be Safe in Some Patients With Metastatic Renal Cell Carcinoma
In a phase II trial reported in The Lancet Oncology, Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, and colleagues found that some patients with metastatic renal cell carcinoma can safely undergo active surveillance for an extended duration prior to initiation of systemic...
High-Intensity Local Treatment in Metastatic Urothelial Carcinoma of the Bladder
In a National Cancer Data Base analysis reported in the Journal of Clinical Oncology, Seisen et al found that high-intensity local treatment was associated with an overall survival benefit in patients with metastatic urothelial carcinoma of the bladder. Quoc-Dien Trinh, MD, of Brigham and Women’s...
Bevacizumab/Capecitabine vs Bevacizumab/Paclitaxel in HER2-Negative Breast Cancer
As reported in The Lancet Oncology by Christoph Zielinski, MD, of the Medical University of Vienna and the Central European Cooperative Oncology Group, and colleagues, the final results of the phase III TURANDOT trial showed that overall survival with first-line bevacizumab (Avastin)/capecitabine...
Tailoring Breast Cancer Screening for Older Women by Breast Density and Risk
A collaborative modeling study evaluating outcomes for various screening intervals for women over the age of 50 based on breast density and risk for breast cancer has found that average-risk women with low breast density undergoing triennial screening and higher-risk women with high breast density...
Risk of Serous/Serous-like Endometrial Carcinoma After RRSO in Women With BRCA1 Mutation
In a prospective cohort study reported in JAMA Oncology, Shu et al found that risk for serous/serous-like endometrial carcinoma appeared to be increased after risk-reducing salpingo-oophorectomy (RRSO) without hysterectomy in women harboring the BRCA1 mutation. The overall risk of uterine cancer...
Lenalidomide/Dexamethasone in High-Risk Smoldering Multiple Myeloma
Long-term follow-up in the phase III QuiRedex trial indicates continued benefit of lenalidomide (Revlimid)/dexamethasone vs observation in preventing disease progression in patients with high-risk smoldering multiple myeloma, as reported by Maria-Victoria Mateos, PhD, of Instituto de Biologia...
HHS Takes Steps to Provide More Information on Clinical Trials to the Public
To make information about clinical trials widely available to the public, the U.S. Department of Health and Human Services (HHS) issued a final rule on September 19 that specifies requirements for registering certain clinical trials and submitting summary results information to ClinicalTrials.gov....
Expect Questions About the FDA Discouraging Use of Ovarian Cancer Screening Tests
The release of a U.S. Food and Drug Administration (FDA) Safety Communication “alerting women about the risks associated with the use of tests being marketed as ovarian cancer screening tests”1 and recommending against using these tests comes not as a result of startling new studies, but from an...
The FDA Urges Physicians and Patients to Forgo Ovarian Cancer Screening Tests
In a Safety Communication directed at women and physicians, the U.S. Food and Drug Administration (FDA) alerted women “about the risks associated with the use of tests being marketed as ovarian cancer screening tests” and recommended “against using currently offered tests to screen for ovarian...
The University of Colorado Cancer Center Names Eric Clambey, PhD, Director of Flow Cytometry Shared Resource
The University of Colorado Cancer Center has named Eric Clambey, PhD, Director of the Flow Cytometry Shared Resource. Dr. Clambey, Assistant Professor in the Department of Anesthesiology, is excited to assume his new role in a vital resource for the cancer center. “My research focuses on the...
The Medical Profession Has to Become Culturally Sensitive to the Needs of LGBT Cancer Survivors
Despite my breast cancer diagnosis 4 years ago, I feel really lucky. My cancer was detected relatively early, stage IIB, during a routine mammogram screening—a test that many of my lesbian friends skip because they don’t want to deal with a medical system steeped in a heterosexual culture that is...
A Space to Heal
We pass them every day on our way to the hospital, the street dwellers of our town in India. Their home consists of a plastic sheet suspended between four poles on the pavement. One day, two women sat under the plastic sheet in happy conversation. It had rained heavily the previous night, and I...
Paul Jacobsen, PhD, Named Associate Director of National Cancer Institute Healthcare Delivery Research Program
Paul Jacobsen, PhD, has been named Associate Director of the National Cancer Institute (NCI) Division of Cancer Control and Population Science’s Healthcare Delivery Research Program. In this position, he will be leading a team at the NCI whose mission is to serve as a catalyst for the field of...
Friendship
Mr. C is almost 90 now, but every summer the boxes of squash, pumpkins, tomatoes, and other vegetables from his truck farm still arrive like clockwork at our door. The cancer that required treatment 17 years ago has never recurred. He’s now struggling with a new problem, recovering from a broken...
Radiologic Associates of Fredericksburg Welcomes Samer Hijaz, MD
Radiologic Associates of Fredericksburg (RAF) has announced that Samer Hijaz, MD, a fellowship-trained interventional radiologist, has joined the practice. The interventional radiologists and vascular surgeons of the RAF serve patients at Virginia Interventional and Vascular Associates, the...
ASCO Recommends ‘Quick Wins’ for National Cancer Moonshot
Last month, ASCO recommended to Vice President Joe Biden several immediate and practical actions the Cancer Moonshot Initiative could take during the remainder of his term in the White House—steps that could make a lasting impact in the effort to discover new cancer treatments. ASCO’s...
ASCO Supports Recent Tobacco Legislation
On August 8, the U.S. Food and Drug Administration’s (FDA) rule giving the agency the authority to regulate e-cigarettes, cigars, hookahs, and pipe tobacco took effect. In May, ASCO applauded the FDA for exercising its congressionally mandated authority to regulate e-cigarettes as a crucial step in ...
Advanced Cancer Care Planning Booklet for Your Patients and Caregivers
The ASCO Answers Advanced Cancer Care Planning booklet contains comprehensive information about how patients can communicate directly and honestly about advanced cancer and end-of-life care with friends, family, children, and the health-care team. Featured content includes: Thorough descriptions...
Are You Ready for MACRA? ASCO Offers Educational Resources and Events to Help Practices Prepare
There are only a few months to go before program changes go into effect under the Medicare Access and CHIP Reauthorization Act (MACRA) on January 1, 2017. MACRA was enacted more than a year ago to replace the Sustainable Growth Rate formula for updates to the Medicare physician fee schedule, and it ...
ASCO International Course Helps Ethiopia Realize Its Goal of Improving Cancer Care
Ethiopia, similar to other African countries, has a significant shortage of physicians. Currently, there are 0.3 physicians for every 100,000 people, a rate that is substantially lower than the 2 physicians per 100,000 people found in the rest of Africa. This year, the First Lady of Ethiopia,...
CCF Conquerors Circle Recognizes Donors
The Conquerors Circle is the Conquer Cancer Foundation’s (CCF) first-ever donor appreciation society. Donors who contribute $1,000 annually are members of the Conquerors Circle. In appreciation for their generous and loyal support of CCF, Conquerors Circle members receive exclusive benefits based...
ASCO President-Elect Bruce E. Johnson, MD, FASCO, Reflects on Volunteer Service, Plans for Presidential Term
Bruce E. Johnson, MD, FASCO, began his term as ASCO President-Elect in June 2016 and will serve as 2017–2018 President. A thoracic cancer specialist, Dr. Johnson is Chief Clinical Research Officer and institute physician at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical...
Bishoy Faltas, MD, Joins Weill Cornell Medicine Hematology and Medical Oncology
On July 1, 2016, Bishoy Faltas, MD, joined the Genitourinary Oncology Program in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. As a laboratory-based physician-scientist, Dr. Faltas will focus on studying mechanisms of mutagenesis and drug resistance in bladder...
Eric Fearon, MD, PhD, Named Director of University of Michigan Comprehensive Cancer Center
Eric Fearon, MD, PhD, has been named Director of the University of Michigan Comprehensive Cancer Center. Dr. Fearon, the Emanuel N. Maisel Professor of Oncology at the University of Michigan, is a nationally recognized investigator in cancer genetics. His research has led to a greater...
Multiple Myeloma Research Foundation to Donate Data to NCI’s Genomic Data Commons
The National Cancer Institute (NCI) recently announced a collaboration with the Multiple Myeloma Research Foundation to incorporate the Foundation’s wealth of genomic and clinical data about the disease into the NCI Genomic Data Commons. NCI’s Genomic Data Commons is a publicly available database...
Susan M. O’Brien, MD, Embraces the Challenge of Balancing Patient Care With Clinical Trial Investigation
Susan M. O’Brien, MD, one of the nation’s foremost leukemia experts, told The ASCO Post that she wanted to become a doctor since her earliest memories. “The idea of being able to help sick people always appealed to me,” said Dr. O’Brien, who was born in Manhattan but spent her formative years in...
Particular HPV Strain Linked to Improved Prognosis for Oropharyngeal Cancer
When it comes to cancer-causing viruses like human papillomavirus (HPV), researchers are continuing to find that infection with one strain may be better than another. In an analysis of survival data for patients with oropharyngeal cancer, researchers from the University of North Carolina (UNC)...
Development and Validation of a Quality Assurance Score for Robot-Assisted Radical Cystectomy
What are the factors that add up to the best outcomes for patients who have surgery to treat cancer? Looking for a better way to measure quality of care and share best practices in surgical oncology, a team from Roswell Park Cancer Institute developed a quality assessment tool and validated it in a ...
Some Gains Reported in Enrollment Disparity in National Lung Cancer Trials
Pang et al found that the enrollment disparity in clinical trials in lung cancer has been reduced in recent years for older patients and women overall, according to a study reported in the Journal of Clinical Oncology. However, disparities persist for elderly women, blacks, Asian/Pacific Islanders, ...
Temozolomide vs Radiotherapy in High-Risk Low-Grade Glioma
In the phase III EORTC (European Organisation for Research and Treatment) 22033-26033 intergroup trial reported in The Lancet Oncology, Baumert et al found no progression-free survival difference between temozolomide chemotherapy and radiotherapy alone in patients with high-risk low-grade glioma....
A Helping Hand, Just in Time: The ASCO Guideline for Managing Chronic Pain in Adult Cancer Survivors
With impeccable timing, as well as considerable forethought and planning, Dr. Paice and colleagues have produced a superb evidence-based guideline on “Management of Chronic Pain in Survivors of Adult Cancers.”1 (See this issue of The ASCO Post.) This summary of well-informed and thoroughly...
ASCO Clinical Practice Guideline on Management of Chronic Pain in Survivors of Adult Cancers
As reported in the Journal of Clinical Oncology by Judith A. Paice, PhD, RN, of Northwestern University, and colleagues, ASCO has released a clinical practice guideline on management of chronic pain in survivors of adult cancers.1 The guideline was based on literature review by an expert panel,...
Small Cell Lung Cancer and Immunotherapy: A Change Is Coming, Just Not Front Line (Yet!)
Ever since the immune checkpoint agents arrived, the pace of clinical investigation in oncology has continued to accelerate with an ever-increasing number of trials of single-agent and combination therapies with novel designs that are transforming our drug-development process. However, even in...
Phase III Trial Finds No Survival Benefit of Adding Ipilimumab to Etoposide/Platinum in Newly Diagnosed Extensive-Stage SCLC
In a phase III trial (CA184-156) reported in the Journal of Clinical Oncology by Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, Germany, and colleagues, the addition of the anti–CTLA-4 (cytotoxic T-lymphocyte–associated protein 4) checkpoint inhibitor ipilimumab (Yervoy) to...
Amelie G. Ramirez, DrPH, Receives AACR Distinguished Lecture on the Science of Cancer Health Disparities
The American Association for Cancer Research (AACR) Distinguished Lecture on the Science of Cancer Health Disparities, funded by Susan G. Komen, honors an investigator whose novel and significant work has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or...
Which Factors Influence Radiotherapy for Brain Metastases?
The advent of more effective systemic therapies, which extend patients’ lives, has also resulted in an increasing incidence of brain metastases, for which clinicians must determine appropriate treatment. Whole-brain radiotherapy has been the traditional treatment modality, but stereotactic...
New Edition of The MD Anderson Manual of Medical Oncology
The third edition of The MD Anderson Manual of Medical Oncology was recently published, offering detailed updates on the personalized multidisciplinary approach to cancer management and treatment of common and rare cancers by specialists at The University of Texas MD Anderson Cancer Center. The...
John Karanicolas, PhD, Joins the Fox Chase Cancer Center Molecular Therapeutics Program
John Karanicolas, PhD, has joined the Fox Chase Cancer Center as Associate Professor in the Molecular Therapeutics Program. Dr. Karanicolas, a computational chemist, earned his doctorate from the Scripps Research Institute. He completed his postdoctoral fellowship at the University of Washington....
Friends of Cancer Research Honors Oncology Leaders at 20th Anniversary and Announces Partnership
Friends of Cancer Research (Friends) celebrated its 20th anniversary September 21 at a special event in Washington, DC. The event honored Janet Woodcock, MD; Eric Lander, PhD; and Sean Parker. Dr. Woodcock, Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug...
Clinical Trials Actively Recruiting Patients With Early Breast Cancer
Pilot Study Title: Pilot Trial of an Implantable Microdevice for in Vivo Drug Sensitivity Testing in Patients With Early-Stage, HER2-Positive, or Triple-Negative Breast Cancer Receiving Neoadjuvant Therapy Study Type: Pilot/interventional/single-group assignment Study Sponsor and Collaborators:...
Using Watson to Analyze Genomic Data to Personalize Treatment for Patients With Cancer
Three years ago, IBM’s Watson supercomputer was best known for defeating two former champions on the TV game show Jeopardy! Today, it is grabbing headlines for becoming an important assistant in cancer care. Able to read and understand millions of pages of text within seconds, Watson caught the...
University of Michigan Cancer Center Names Four New Leaders
The University of Michigan (U-M) Comprehensive Cancer Center has appointed four new leaders to oversee the direction and operation of its research enterprise. Pavan Reddy, MD, Deputy Director Alnawaz Rehemtulla, PhD, Associate Director for Shared Resources Anne Schott, MD, Associate Director for...
2016-2017 Oncology Meetings
OCTOBER American College of Surgeons Clinical CongressOctober 16-20 • Washington, DCFor more information:www.facs.org/clincon2016 ACCC 33rd National Oncology ConferenceOctober 19-21 • St. Louis, Missouri For more information: www.accc-cancer.org/meetings/slideshow-NOC2015/NOC2015.asp 48th Annual...
